Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

Markov model structure with the three health states.

More »

Fig 1 Expand

Table 1.

Input parameters used in the model.

More »

Table 1 Expand

Table 2.

Number of uHCC patients corresponding to atezolizumab+bevacizumab accessibility.

More »

Table 2 Expand

Fig 2.

Predicted overall survival of patients who received atezolizumab plus bevacizumab (A+B) and best supportive care (BSC). Abbreviation: A+B, atezolizumab plus bevacizumab; BSC, best supportive care.

More »

Fig 2 Expand

Table 3.

Incremental cost-effectiveness ratios (ICER, in USD/QALY).

More »

Table 3 Expand

Fig 3.

Cost-effectiveness acceptability curve. Abbreviation: A+B, atezolizumab plus bevacizumab; QALY, quality-adjusted life year; USD, the United States dollar.

More »

Fig 3 Expand

Fig 4.

One-way sensitivity analysis on changes in base case ICER for atezolizumab plus bevacizumab (A+B) versus best supportive care (BSC).

Abbreviation: AB, atezolizumab plus bevacizumab; BSC, best supportive care; CI, confidence interval; ICER, incremental cost-effectiveness ratio; HR, hazard ratio; PFS, progression free survival; OS, overall survival.

More »

Fig 4 Expand

Fig 5.

Five-year budget estimation.

Abbreviation: USD, the United States dollar.

More »

Fig 5 Expand